- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Flatiron's OncologyCloud Could be Big News
OncologyCloud, a platform developed by Flatiron Health, is already in partnership with more than 25 cancer centers to help address some of the bottlenecks in cancer care.
When Flatiron Health emerged in 2012 with a mission to improve oncology care, its founder predicted it would either be "a great success or a horrible failure." Now the Big Data startup is reportedly on the cusp of taking a major step towards the better of these two outcomes, with Fortune writing Google's ($GOOG) venture capital wing is leading a $100 million financing round.
Flatiron has established links to Google. The oncology startup's founders sold their last business to the search giant for $81 million. After leaving Google, the founders, Zach Weinberg and Nat Turner, set up Flatiron, began talking to physicians about the main bottlenecks in cancer care and created a Big Data platform to address some of the problems. The platform, OncologyCloud, aggregates clinical and financial data from electronic medical records and billing systems.
Read the report and associated news:
Source: FierceBiotechIT
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
